Anavex Life Sciences Corp.
AVXL
$2.76
-$0.10-3.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.03M | 2.29M | 2.13M | 3.55M | 4.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.77M | 6.46M | 6.75M | 10.83M | 14.33M |
| Operating Income | 6.77M | -6.46M | -6.75M | -10.83M | -14.33M |
| Income Before Tax | 7.82M | -5.34M | -5.66M | -9.83M | -13.24M |
| Income Tax Expenses | -- | -- | 18.00K | -- | -- |
| Earnings from Continuing Operations | 7.82M | -5.34M | -5.68M | -9.83M | -13.24M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.82M | -5.34M | -5.68M | -9.83M | -13.24M |
| EBIT | 6.77M | -6.46M | -6.75M | -10.83M | -14.33M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.08 | -0.06 | -0.06 | -0.11 | -0.16 |
| Normalized Basic EPS | 0.05 | -0.04 | -0.04 | -0.07 | -0.10 |
| EPS Diluted | 0.08 | -0.06 | -0.06 | -0.11 | -0.16 |
| Normalized Diluted EPS | 0.05 | -0.04 | -0.04 | -0.07 | -0.10 |
| Average Basic Shares Outstanding | 92.70M | 92.68M | 89.03M | 85.89M | 85.38M |
| Average Diluted Shares Outstanding | 92.90M | 92.68M | 89.03M | 85.89M | 85.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |